Skip to main content
Clinical Trials/NCT05467228
NCT05467228
Withdrawn
Phase 2

Laryngeal Vibro-tactile Stimulation as a Non-invasive Symptomatic Treatment for Spasmodic Dysphonia

University of Minnesota1 site in 1 country60 target enrollmentAugust 2026

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Adductor Spasmodic Dysphonia
Sponsor
University of Minnesota
Enrollment
60
Locations
1
Primary Endpoint
Change in perceived speech effort (PSE)
Status
Withdrawn
Last Updated
11 months ago

Overview

Brief Summary

The general aim of the research is to provide scientific evidence that vibro-tactile stimulation (VTS) represents a non-invasive form of neuromodulation that can induce measurable improvements in the speech of patients with laryngeal dystonia (LD) - also called spasmodic dysphonia (SD).

Registry
clinicaltrials.gov
Start Date
August 2026
End Date
August 1, 2026
Last Updated
11 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Confirmed diagnosis of adductor or abductor LD for a minimum of 6 months.

Exclusion Criteria

  • Regular intake of benzodiazepines
  • Cognitive impairment: score \< 27 on the Mini-mental State Examination (MMSE).
  • Identify with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia other than LD, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis.
  • Non-English speaker. We will not enroll people who cannot speak English, because the voice assessment procedures (Test sentences, CAPE_V clinical rating) have only been validated for English speakers at this point.
  • Pregnant people. We will not enroll pregnant people as the device used in this study is investigational.

Outcomes

Primary Outcomes

Change in perceived speech effort (PSE)

Time Frame: 24 months

Speaker will assess effort themselves and assign an score (range: 0-10 with a score of '10' indicating most severe effort)

Change in speech quality vector (SQV) (%)

Time Frame: 24 months

A derived measure designed to understand if a participant's voice symptom improvement occurs across objective (CPPS) and subjective measures of speech (PSE). It is based on the relative change between two time points

Change in smoothed cepstral peak prominence (CPPS)

Time Frame: 24 months

CPPS provides a measure of the strength of the fundamental frequency within background aperiodicity (physical unit is dB)

Study Sites (1)

Loading locations...

Similar Trials